ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Durham, NC, USA:

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non...

Enrolling
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Drug: DTRM-555

Phase 2

Zhejiang DTRM Biopharma

Durham, North Carolina, United States and 7 other locations

This study has 2 parts.The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non...

Active, not recruiting
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Chemotherapy Agents
Biological: TAK-007

Phase 2

Takeda
Takeda

Durham, North Carolina, United States and 14 other locations

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical a...

Enrolling
Non-Hodgkin Lymphoma
B-cell Acute Lymphoblastic Leukemia
Drug: Cyclophosphamide
Drug: Fludarabine

Phase 1

Imugene

Durham, North Carolina, United States and 20 other locations

evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Obinutuzumab
Drug: Zanubrutinib

Phase 2

BeiGene
BeiGene

Durham, North Carolina, United States and 119 other locations

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malig...

Active, not recruiting
B-cell Lymphoma
Non-Hodgkin Lymphoma
Biological: CTX110

Phase 1, Phase 2

CRISPR Therapeutics
CRISPR Therapeutics

Durham, North Carolina, United States and 32 other locations

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Raleigh, North Carolina, United States and 126 other locations

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Drug: Venetoclax
Drug: Rituximab

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Durham, North Carolina, United States and 55 other locations

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research.Adults with non-Hodgkin...

Active, not recruiting
Lymphoma, Malignant
Non-hodgkin Lymphoma
Drug: DS-3201b

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Durham, North Carolina, United States and 20 other locations

is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL)....

Enrolling
Follicular Lymphoma (FL)
Drug: Odronextamab
Drug: Rituximab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Chapel Hill, North Carolina, United States and 90 other locations

The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (called "previously untreated"...

Enrolling
Diffuse Large B-cell Lymphoma (DLBCL)
Drug: Doxorubicin
Drug: Prednisone/Prednisolone

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Durham, North Carolina, United States and 103 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems